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Suppressive Effect of Mitomycin C (MMC) on Liver Recurrence 
from Gastric VX2 Cancer Lesions 
Yoshiki Tabuchi1 , Yasuyuki Tada2 , Masayoshi Sakane2 , Shiro N akae2 , 
and Takeshi Nakamura2 
The suppresive effects of mitomycin C (MMC) on liver recurrence were examined 
by varying the injection doses and routes in 45 gastric cancer rabbits. The 
primary cancer lesions without metastasis were resected 14 days after implanta-
tion of VX2 cancer, and the animals were autopsied 14 days after resection. 
Liver recurrence was found in 90 % of control animals, but was not found in 
animals which received postoperative portal MMC 0.5 and 0.25 mg/Kg and 
peripheral MMC 1.0 mg/Kg injections. The recurrence rate was significantly 
higher in the control than in the MMC injected animals. The recurrence was 
found in 86 and 71 % of animals which received postoperative portal MMC 0.125 
mg/Kg and peripheral MMC 0.5 mg/Kg injections, respectively. No significant 
difference was found in the rates between the control and these MMC injected 
animals. These results suggest that portal MMC injection is more effective for 
the suppression of liver recurrence than the peripheral injection and that the 
efficacy dose of the former is almost the same as the 1/4 dose of the latter. 
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INTRODUCTION 
Li ver metastasis and recurrence 
frequently occur in gastrointestinal 
cancer patients and is one of the main 
causes of cancer death (1,2). The 
mechanism and extension process 
have been gradually explained (3-6), 
and various effective therapies for the 
metastasis have been developed re-
cently (7,8). In spite of extensive 
Faculty of Health Science l and First Depart-
ment of Surqerl, Kobe University School of 
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studies (1,2), however, reliable sup-
pressive therapies for liver recur-
rence have not yet been established, 
although a few reports have shown 
some positive findings (9,10). 
In the present study, an ex-
perimental model with a high frequen-
cy of liver recurrence after resection 
of primary gastric cancer lesions in-
duced by implantation of VX2 cancer 
cells into the stomach was established 
for rabbits, and the suppreSSIve 
effects of an anti -cancer agent, 
mitomycin C (MMC), on the recur-
rence according to different injection 
doses and routes were examined and 
discussed. 
MATERIALS AND METHODS 
1. VX2 cancer and suspension of 
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VX2 cancer cells 
The VX2 cancer cells, originally 
established by Rous and co-workers 
(11), were maintained by successive 
transplantation into the hind leg-
muscle of Japanese white female rab-
bits at intervals of approximately 3 
weeks. Immediately after sacrifice of 
donor rabbits under venous anesthe-
sia by overdose of sodium pentobar-
bital, the VX2 cancer was aseptically 
stripped from the surrounding mus-
cles and connective tissue and minced 
mechanically with scissors in a cold 
(4°C) phosphate buffer solution 
(PBS), as previously reported by us 
(12-14). In brief, after the mecha-
nical mincing, the supernate including 
necrotic debris was discarded. The 
specimens were further minced in a 
newly added PBS and the cell suspen-
sion was filtered through an iron 
mesh with 0.08 mm 2 pores to remove 
macroscopic fragments. Thereafter, 
the suspension was centrifuged at 
800 rpm for 10 minutes and the su-
pernate was discarded. The proce-
dure was repeated twice with the 
addition of cold PBS in order to 
obtain a pure cancer cell suspension. 
Dead cells stained with trip an blue 
were counted, and then viable cells 
were adjusted to a concentration of 
1 X 107 cells/ml. The resulting cell 
suspension contained not only single 
cells but also tiny and compact 
clumps consisting of 5-20 cancer 
cells (12). 
2. Implantation of VX2 cancer cells 
and experimental animal groups 
Fifty-two Japanese white female 
rabbits, each weighing about 2 Kg, 
were used. Under intravenous anes-
thesia of sodium pentobarbital 
(30mg/Kg), laparotomy was per-
formed, and 0.1 ml (1 X 106 cells) of 
the suspension was implanted by a 
26-gauge needle from the serosal site 
into the subserosa and/or proper 
muscle layers into the anterior wall of 
the gastric body, after no back-flow 
of blood into the needle or syringe 
was confirmed. Immediately after im-
plantation, a minute nodule was 
formed, and the aperture was closed 
by a mosquito clamp and then ligated 
with 3-0 surgical silk to avoid bleed-
ing and leakage of cancer cells 
(12-14). 
The animals were divided into 3 ex-
perimental groups : Group 1; MMC 
(Kyowa Hako Kogyo Co. Ltd., Tokyo, 
Japan) non-injected control group, 
Group 2; peripheral MMC injected 
group, Group 3; portal MMC injected 
group. Groups 1, 2 and 3 consisted 
of 12, 16 and 24 animals, respecti ve-
ly. All the primary gastric lesions 
were resected 14 days' after implanta-
tion at a distance of 1.5 cm from the 
edge of the tumors, followed by a 
two-layer suture of the resected areas 
(14) . At the time of resection, peri-
and paragastric nodes were also re-
sected as much as possible. Four ml 
of PBS was injected into the portal 
vein through a mesenteric vein just 
after resection of cancer lesions in 
Group 1. In Groups 2A and 2B each 
consisting of 8 animals, 4 ml of PBS 
containing MMC 1.0 and 0.5 mg/Kg 
was peripherally injected into the au-
ricular vein just after resection. In 
Groups 3A, 3B and 3C each consist-
ing of 8 animals, 4 ml of PBS contain-
ing MMC 0.5, 0.25 and 0.125 mg/Kg 
was injected into the portal vein 
through a mesenteric vein just after 
resection. Autopsy was performed in 
all the animals under overdose of 
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venous anesthesia, and cancer metas-
tatic and/or recurrent lesions in the 
abdominal and thoracic organs were 
examined macro- and microscopically. 
3. Macroscopic and microscopic ob-
servation of specimens 
All the abdominal organs, including 
the liver, peritoneum and lymph nodes 
adj acent to the stomach and celiac 
artery, were examined macroscopical-
ly during the time of tumor resection, 
and the abdominal and thoracic 
organs were resected from each auto-
psied animal. The nodes were re-
sected mainly from the peri-and pa-
ragastric areas, celiac and mesenteric 
arteries and aorta. After the macro-
Q~opic observation of all the speci-
'S, followed by the measurement 
anJ record of cancer lesions when 
they were found, the specimens were 
fixed in 10 % neutral formalin solu-
tion for 14 days. 
The fixed nodes, gastric cancer le-
sions and the stomachs resected 14 
days after implantation and autopsy 
were examined by studying 3 sections 
which consisted of a central section 
and 2 parallel sections of the margins 
along the central section. The ex-
amination process for each liver and 
lungs began with slicing sections 5 
mm thick and studying 4 sections; 
When cancer lesions were macroscop-
ically detected, their number and di-
ameter were recorded. Two sections 
were obtained from the liver and lung 
tissues with cancer lesions, and the 
other sections were taken from the 
tissues without cancer lesions. Each 
section was stained with hematoxylin 
and eosin (HE), elastica van Gieson 
stain and/ or resorcin -fuchsin 
(Weigert) HE stain (15), and ex-
amined microscopically. 
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4. Statistical analysis 
The data were analyzed by the 
chi-square test and Student's t test. 
RESULTS 
1. Gastric, metastatic and/or recur-
rent cancer lesions in Group 1 
(control MMC non-injected group) 
In this group, 2 out of 12 animals 
died of peritonitis 1 and 2 days after 
resection of gastric cancer lesion, and 
the other animals survived throughout 
the experimental days. Thus, 10 
animals were autopsied and examined 
carefully. The results are summa-
rized in Tables 1 and 2. 
Macroscopically, the gastric cancer 
lesions consisted of 7 submucosal 
mass types and 3 ulcerative mass 
types 14 days after implantation (Fig. 
1 ) . The mean diameter of the le-
sions was 9.2 mm (Table 1). Micro-
scopically, VX2 cancer cells with cen-
tral necroses grew among the sub-
serosal and mucosal layers not only in 
ulcerative mass but also in submucos-
al mass types, and vascular invasion 
was mainly found in the submucosal 
and subserosal layers (Fig. 2). Re-
garding the invasion, venous and lym-
phatic invasions were verified in 8 
(80 %) and 6 (60 %) out of 10 anim-
als respectively (Table 2). 
At the time of gastric cancer resec-
tion, no metastasis in the peritoneum, 
liver, lymphnodes and abdominal wall 
was found in any animal macroscopi-
cally. Microscopically, metastasis was 
not found in the animals which died of 
peritonitis 1 and 2 days after resec-
tion. However, multiple liver recurr-
ence was found in 9 (90 %) out of 10 
animals at the time of autopsy (Fig. 
3 ) . The mean number and diameter 
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Table. 1 Macroscopic type, average diameter and vascular invasion of gastric VX2 cancer lesions at the 
time of resection in Groups 1,2 and 3. 
Experimental NoB Macroscopic type Diameter C Vascular Invasion(') 
group ------------------ (nun) ---------------------
Submu b Ulcer b Lymphatic Venous 
Group 1 10 7 3 9.2 ± 0.5 6 (60) 8 (80) 
Group- 2 14 9 5 9.3 ± 0.6 7 (50) 11 (84) 
Group 3 21 14 7 8.8 ± 0.8 13 (62) 17 ( 81) 
BNumber of animals. bSubmu and Ulcer in macroscopic type: submucosal 
and ulcerative mass types. c Mean ± standard error(SE). 
of cancer recurrence in the liver were, 
respectively, 76.4 nodules and 4.2 
mm (Table 2). Two (10 %) of 
these animals showed multiple nodal 
recurrence adjacent to the celiac 
artery. In the animals, peritoneal re-
currence was also found. Microscop-
ically, cancer nodules in the liver 
were mainly present in the perilobu-
lar areas, accompanied by many can-
cer emboli, with or without invasion 
into the parenchyma, in the interlobu-
lar veins and/or inlet venules and 
were found within 6 mm of the mac-
roscopically recognizable nodules 
(Fig. 4). 
2. Gastric, metastatic and/or recur-
rent cancer lesions in Group 2 
(peripheral MMC injected group) 
Two animals in Group 2 died 1 and 
2 days after resection of gastric can-
cer lesions, but the other animals sur-
vived up to the autopsy day. In this 
group, cancer metastasis was not 
found in any animal at the time of 
gastric cancer resection. The results 
in this group are also summarized in 
Tables 1 and 2. The macroscopic 
type, mean diameter and rate of 
vascular invasion at the time of resec-
tion in this group were not different 
from those in Group 1 (Table 1). 
Multiple liver recurrence was not 
found in 7 animals of Group 2A 
macro- and microscopically, although 
5 (71 %) out of 7 animals showed the 
recurrence in Group 2B. The recur-
rence findings were almost the same 
as those of the control group macro-
and microscopically. The recurrence 
rate in the animals in Group 2A was 
significantly lower than that in Group 
1 (Table 2). However, no significant 
difference was found in the rates be-
tween the animals of Groups 1 and 
2B. The number and diameter of liv-
er recurrent nodules in the animals of 
Group 2B were not different' from 
those in the animals of Group 1 
(Table 2). In this group, 2 (14 %) 
animals showed multiple nodal recur-
rence adjacent to the celiac artery. 
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Figure 1. Macroscopic type of gastric VX2 
cancer lesions 14 days after im-
plantation. A and B show sub-
mucosal and ulcerative mass type, 
respectively. One graduation re-
presents 5 mm. 
However, no cancer recurrence was 
found in the other organs. 
3. Gastric, metastatic and/or recur-
rent cancer lesions in Group 3 (portal 
MMC injected group) 
In this group, ~ and 1 animals died 
of peritonitis 1 and 2 days after re-
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Figure 2. Microscopic findings of Figure 1 A. 
VX2 cancer cells grow in the sub-
mucosal and also in the mucosal 
layers. Arrows indicate the in-
vaded veins. Resorcin - fuchsin 
(Weigert) HE stain, X 60. 
section respectively. However, the 
other animals survived up to the auto-
psy day. Cancer metastasis was not 
found in any animals at the time of 
~astric cancer resection also in this 
group. The findings of primary gas-
tric cancer lesions were not different 
from those in Groups 1 and 2, as 
shown in Table 1 (Table 1). 
In Groups 3A and 3B, multiple liv-
er recurrence was not confirmed 
macro- and microscopically in any 
animals, and the recurrent rate was 
significantly lower than· that in the 
control group (Table 2); However, 
the recurrence was found in 6 (86 %) 
out of 7 animals in Group 3C, and the 
recurrent rate was not different from 
that in the control group. The num-
ber and diameter of the recurrent 
nodules were not also different from 
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Figure 3. Multiple liver recurrence (white 
nodules) 14 days after resection 
of gastric VX2 cancer lesion. One 
graduation. represents 5 mm. 
those in the control group (Table 2). 
Multiple nodal recurrence was also 
found in 4 (19 %) out of 21 animals 
in Group 3 and the recurrence rate 
was not different from those In 
Groups 1 and 2. However, no cancer 
recurrence was also found in the 
other organs of this group. 
DISCUSSION 
In general, liver recurrence from 
the gastrointestinal cancer lesions has 
been thought to originate mainly from 
two sources; (1) postoperative grow-
th of preoperative micrometastasis in 
the liver and (2) formation of liver 
metastasis due to the entry of cancer 
cells and/or clusters into the portal 
vein during the period of operation 
(3-5,13,14,16-18). In the present 
Figure 4. Microscopic findings of liver re-
currence nodules. The recurrence 
nodules are mainly present in the 
perilobular areas (A). Cancer em-
boli (arrows) are found in the in-
terlobular veins at a distance a-
bout 5 mm from the macroscopical-
ly recognizable nodules in Figure 
4A (B). Resorcin-fuchsin (Weige-
rt) HE stain, X 60 (A) and X 240 
(B) . 
study, cancer metastasis was not 
found in any animal at the time of 
primary cancer resection. However, 
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Table. 2 Number of animals with liver recurrence, mean number of recurrent nodules and diameter of the 
nodules at the time of autopsy in Groups 1,2 and 3. 
Experimental NoB Dose of MMC Liver recurrence 
group (mg/Kg) --------------------------------------------
Animals(%) Nodules b Diameterb(mm) 
Group 1 10 0~000 9 (90) 76.4 ± 26.8 4.2 ± 2.4 
Group 2A 7 1.000 0 ( O)t 
2B 7 0.500 5 (71) 55.3 ± 38.7 3.9 ± 1 .8 
Group 3A 7 0.500 0 ( O)t 
3B 7 0.250 0 ( O)t 
3C 7 0.125 6 (86) 63.5 ± 34.9 5. 1 ± 4.8 
BNumber of animals. b Mean ± standard error (SE). 
tSignificant difference from Group 1 
cancer recurrence was found in the 
liver of almost all the control animals 
and in the lymphnodes of a few anim-
als at the time of autopsy. Recurrent 
nodules in the liver were mainly 
found in the perilobular areas, almost 
always accompanied by cancer emboli 
in the interlobular veins and/or inlet 
venules, as precisely reported by us 
(12 -14) . These findings are almost 
the same as those seen in the liver 
metastases induced by the portal im-
plantation of VX2 cancer cell suspen-
sion (12). Therefore, the aforemen-
tioned (1) or (2) sources seems to 
play an important role in the forma-
tion and extension of liver recurrence. 
Liver recurrence was completely 
suppressed and was not detected in 
any animal which received peripheral 
MMC 1.0 mg/Kg and portal MMC 0.5 
and 0.25 mg/Kg injections. The re-
current rate was significantly lower 
Vol. 10, 1994 
(P < 0.01). 
than that in the control animals. 
However, the recurrence was found in 
71 % and 86 % of the animals which 
received the peripheral 0.5 mg/Kg 
and portal 0.125 mg/Kg injections re-
spectively, and the recurrent rates 
were not different from the rate in the 
control animals. These results clear-
ly indicate that a suppressive effect 
on the liver recurrence is more easily 
obtained by portal injection than by 
peripheral injection and that the 
efficacy dose of portal MMC injection 
is almost the same as the 1/4 dose of 
peripheral injection. 
The cancer suppressive efficacy of 
anti -cancer agents is generally be-
lieved to be influenced mainly by the 
sensitivity of the cancer cells them-
selves to the agents and blood supply 
in the cancer lesions (19). VX2 can-
cer cells have been found to have a 
high sensitivity to MMC (12,20). 
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Regarding the blood supply, some in-
vestigators have reported that liver 
metastatic nodules are fed mainly by 
arterial blood (3,5,21) . However, 
macroscopically non-recognizable mi-
crometastases in the liver have been 
reported to be supplied by the portal 
blood rather than by the arterial 
blood, although arterial blood supply 
becomes gradually dominant as they 
grow (22-24). In our previous 
study, no significant difference in 
MMC concentration 1 minute after 
portal and peripheral injections has 
been found between the liver tissues 
and portal blood, and MMC has been 
confirmed to be rapidly inactivated in 
the liver (12). From the results and 
observations, a higher concentration 
of MMC just after the portal than 
peripheral injections seems to act 
against the perilobular micrometas-
tases and/or cancer cells in the inter-
lobular veins or inlet venules for a 
very short period and to suppress the 
recurrence. Furthermore, liver func-
tion induced by a dose of MMC 1.0 
mg/Kg has been found to be slight, 
and the degree of the bone marrow 
suppression after the portal injection 
has also been found to be much smal-
ler than after the peripheral injection 
(12). Thus, portal injection of MMC 
has been confirmed to be more effec-
tive for liver recurrence than the 
peripheral injection not only theoreti-
cally but also practically. 
Many trials of surgical adjuvant 
chemotherapy for gastrointestinal can-
cer patients have been performed be-
fore and/or after operation and are in 
progress (1,2,10). Systemic admin-
istration of anti -cancer agents with or 
without biochemical modulators for 
the purpose of liver recurrence has 
been reported to have no or little 
efficacy in general, except for a few 
successful reports (26-28). Howev-
er, local administration of the agents 
for this purpose has been reported to 
be effective by some investigators 
(9,1 0,29) . One of the successful re-
ports by Taylor and co-workers has 
demonstrated that postoperative por-
tal inj ection of the cytotoxic 
anti-cancer agent, 5-FU, is effective 
as an adjuvant chemotherapy for col-
orectal cancer patients (9). Recent-
ly, Metzger and co-workers have also 
reported the effectiveness of portal in-
fusion of the anti-cancer agents, 5-
FU and MMC, as an adjuvant che-
motherapy without significantly in-
creasing morbidity and mortality 
(10). The present results may not 
necessarily be applicable to gastroin-
testinal cancer patients, because the 
VX2 cancer model has a high sensitiv-
ity to MMC (12,20) and exhibits a 
faster growth than liver recurrence in 
human gastrointestinal cancer. 
However, the results clearly suggest 
that suppression of the recurrence can 
be more easily obtained by portal 
than by peripheral MMC administra-
tion while decreasing the side effects 
(12) . If the portal administration 
for suppression of liver recurrence is 
designed as an adjuvant chemother-
apy, portal injection should be started 
as soon as possible after resection of 
cancer lesions when tumor burden is 
minimal (19,30), and the continuous 
or intermittent and/or combination in-
fusion of anti -cancer agents through 
the portal catheter from a branch of 
the mesenteric vein (10) may be re-
commended, because the approach is 
easily feasible. When the portal infu-
sion is indicated for the recently de-
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scribed high risk patients with liver 
recurrence (31,35) as well as for pa-
tients with high frequency of recur-
rence in the remaining liver under-
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